Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine

Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures and venBio Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology Commenced Phase I clinical study of…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.